Jin Hong, Liang Yundan, Wang Xunli, Zhu Jingqiang, Sun Ruifen, Chen Peng, Nie Xinwen, Gao Linbo, Zhang Lin
Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Med Oncol. 2014 Oct;31(10):221. doi: 10.1007/s12032-014-0221-3. Epub 2014 Sep 9.
KRAS mutation is frequently detected in a series of cancers, including papillary thyroid cancer (PTC). Recently, a genetic variant of rs712 in the 3' untranslated region of the KRAS gene has been reported to be functional in the regulation of KRAS by disrupting complementary site of let-7 and miR-181. We aimed to investigate whether the polymorphism is a risk factor for PTC. We conducted an association study, including 252 PTC patients and 290 healthy controls. The KRAS rs712 polymorphism was genotyped by polymerase chain reaction-restriction fragment length polymorphism. Although no significant difference of the KRAS rs712 distribution was observed between cases and controls in overall analysis, stratification analysis showed that patients carrying the KRAS rs712TT genotype were less likely to develop stages T3 and T4 under a recessive genetic model (OR 0.26, 95% CI 0.08-0.82). These results supported the role of the KRAS rs712 polymorphism as a potential genetic biomarker for the extension of PTC. Further population-based association studies are of great value to confirm the results in diverse ethnicities.
KRAS突变在包括甲状腺乳头状癌（PTC）在内的一系列癌症中经常被检测到。最近，据报道KRAS基因3'非翻译区的rs712基因变异通过破坏let-7和miR-181的互补位点在KRAS调控中发挥作用。我们旨在研究该多态性是否是PTC的危险因素。我们进行了一项关联研究，包括252例PTC患者和290例健康对照。通过聚合酶链反应-限制性片段长度多态性对KRAS rs712多态性进行基因分型。虽然在总体分析中病例组和对照组之间未观察到KRAS rs712分布的显著差异，但分层分析显示，在隐性遗传模型下，携带KRAS rs712TT基因型的患者发生T3和T4期的可能性较小（OR 0.26，95%CI 0.08-0.82）。这些结果支持KRAS rs712多态性作为PTC扩展潜在遗传生物标志物的作用。进一步基于人群的关联研究对于在不同种族中证实结果具有重要价值。
